Candel Shares Fall on Wider Loss From Operation, FDA Discussion
By Natalie WegerShares of Candel Therapeutics fell after the company posted a wider loss from operations and said it's in ongoing dialogue with the Food and Drug Administration about a license application.Shares dropped 38% to $5.15 in after-hours trading on Thursday. The stock was down 9% through…
Story updates
11:13:43 PM UTC
SquawkNews
Shares of Candel Therapeutics (CADL) sold off 38% in after-hours trading on Thursday after the company said ongoing discussions with the U.S. Food and Drug Administration (FDA) have delayed its planned Biologics License Application for lead candidate aglatimagene besadenovec in localized prostate c…